

## Supplementary Information

Pre-formulation of an additive combination of two  
antimicrobial agents, clofazimine and nisin A, to  
boost antimicrobial activity.

*Mateo Flores Naranjo<sup>1</sup>, Ajay Kumar<sup>1</sup>, Poonam Ratrey<sup>1</sup>, Sarah P. Hudson<sup>1\*</sup>*

*<sup>1</sup>Department of Chemical Sciences, SSPC, the Science Foundation Ireland Research Centre for  
Pharmaceuticals, Bernal Institute, University of Limerick, Castletroy, Limerick, V94 T9PX,  
Ireland.*

*\*Correspondence: [sarah.hudson@ul.ie](mailto:sarah.hudson@ul.ie)*

## Table of Contents

Conditions screened for preparation of CFZ nanoparticles by liquid antisolvent precipitation	2
Particle size distributions	3
FTIR and SSNMR Analysis	4

**Conditions screened for preparation of CFZ nanoparticles by liquid antisolvent precipitation.**

Table S1. List of stabilizers and concentrations screened in the antisolvent phase for the antisolvent precipitation of CFZ particles.

Anti-solvent	Stabilizers	Z-Average Size (nm)	PDI	Zeta Potential (mV)
<b>HCl/KCl pH 2.0 buffer</b>	---	996	0.746	24.5 ± 1.21
	0.2% w/v Nisin A	568	0.637	
	0.2% w/v PVP	729	0.815	
	0.2% w/v Nisin A + 0.2% w/v PVP	164	0.361	
	0.4% w/v Nisin A + 0.2% w/v PVP	201	0.283	17.06 ± 1.29
	0.2% w/v Nisin A + 0.3% w/v PVP	210	0.299	
	0.2% w/v Nisin A + 0.2% w/v Pluronic F-127	1563	0.454	
	0.2% w/v Nisin A + 0.2% w/v PVP + 0.2% Pluronic F-127	3019	0.538	
	0.2% w/v Nisin A + 0.2% w/v PVA	500	0.823	
	0.1% w/v Nisin A + 0.1% w/v HPMC + 0.05% w/v lecithin	394	0.557	
	0.2% w/v Nisin A + 0.2% w/v PVP + 0.05% lecithin	290	0.873	
	0.5% lecithin (+ CFZ in THF) into 0.2% Nisin A + 0.2% PVP	1385	0.568	
	0.5% lecithin (+ CFZ in THF) into 0.2% Nisin A + 0.4% PVP	1108	0.468	
<b>0.1% TFA (aq.)</b>	---	228	0.372	54.7 ± 2.44
	0.4% w/v Nisin A	166	0.241	26.9 ± 1.04
	0.2% w/v PVP	210	0.296	
	0.2% w/v Nisin A + 0.2% PVP	178	0.198	
	0.2% w/v Nisin A + 0.3% PVP	178	0.264	
	0.2% w/v Nisin A + 0.4% PVP	187	0.277	
	0.3% w/v Nisin A + 0.2% PVP	171	0.226	
	0.4% w/v Nisin A + 0.2% PVP	173	0.154	28.87 ± 1.14

## Particle size distributions




Figure S1. Particle size distribution over time of CFZ- salt nanosuspension in the presence of nisin A. Formulation: 0.3 mL 50 mg/mL CFZ in THF into 20 mL 0.4% v/w nisin A in 0.1% TFA (aq.)




Figure S2. Particle size distribution and average size values of CFZ- salt nanosuspension in the absence of nisin A over time. Formulation: 0.3 mL 50 mg/mL CFZ in THF into 20 mL in 0.1% TFA (aq.)




Figure S3. Particle size distribution and average size values of micron-sized CFZ TFA<sup>-</sup> salt particles. Formulation: 1 mL of 250 mg/mL CFZ in THF into 100 mL 1 M TFA (aq.).

## FTIR and SSNMR Analysis




Figure S4. FTIR spectra of CFZ species precipitated in different antisolvents




Figure S5.  $^{13}\text{C}$  CPMAS SSNMR of CFZ species and nisin A